Vamil Divan
Stock Analyst at Guggenheim
(4.58)
# 235
Out of 4,910 analysts
238
Total ratings
64.81%
Success rate
15.48%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $164 → $167 | $169.56 | -1.51% | 16 | Jul 17, 2025 | |
| PROK ProKidney | Maintains: Buy | $6 → $7 | $3.26 | +114.72% | 2 | Jul 14, 2025 | |
| JBIO Jade Biosciences | Upgrades: Buy | $14 | $8.33 | +68.07% | 1 | Jun 16, 2025 | |
| SVRA Savara | Maintains: Buy | $9 → $8 | $2.55 | +213.73% | 1 | May 28, 2025 | |
| AMGN Amgen | Assumes: Neutral | $288 | $308.55 | -6.66% | 1 | May 20, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $86 | $66.77 | +28.80% | 11 | May 12, 2025 | |
| VALN Valneva SE | Maintains: Buy | $15 → $14 | $7.59 | +84.53% | 1 | May 8, 2025 | |
| ABBV AbbVie | Maintains: Buy | $214 → $216 | $190.83 | +13.19% | 26 | Apr 29, 2025 | |
| UNCY Unicycive Therapeutics | Initiates: Buy | $60 | $4.85 | +1,137.11% | 1 | Apr 21, 2025 | |
| MRK Merck & Co. | Reiterates: Buy | $115 | $84.11 | +36.73% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $15.96 | +194.49% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $18.30 | +69.40% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.51 | +184.90% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $25.35 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $21.88 | +178.79% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $101 | $103.52 | -2.43% | 6 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $14.38 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $8.76 | +128.31% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.67 | +3,808.60% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.74 | +1,119.51% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.78 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $23.06 | -17.59% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $131.64 | -25.55% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $26.53 | +28.16% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.66 | +502.41% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $104.97 | -53.32% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $805.43 | -55.80% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $5.17 | +16.05% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $13.69 | +1,024.91% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $9.64 | +55.68% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $30.84 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $16.33 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $4.75 | +215.79% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $48.94 | +24.64% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $1.49 | +6,812.75% | 3 | Jan 17, 2018 |
Johnson & Johnson
Jul 17, 2025
Maintains: Neutral
Price Target: $164 → $167
Current: $169.56
Upside: -1.51%
ProKidney
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $3.26
Upside: +114.72%
Jade Biosciences
Jun 16, 2025
Upgrades: Buy
Price Target: $14
Current: $8.33
Upside: +68.07%
Savara
May 28, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.55
Upside: +213.73%
Amgen
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $308.55
Upside: -6.66%
ANI Pharmaceuticals
May 12, 2025
Reiterates: Buy
Price Target: $86
Current: $66.77
Upside: +28.80%
Valneva SE
May 8, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $7.59
Upside: +84.53%
AbbVie
Apr 29, 2025
Maintains: Buy
Price Target: $214 → $216
Current: $190.83
Upside: +13.19%
Unicycive Therapeutics
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $4.85
Upside: +1,137.11%
Merck & Co.
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $84.11
Upside: +36.73%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $15.96
Upside: +194.49%
Mar 25, 2025
Initiates: Buy
Price Target: $31
Current: $18.30
Upside: +69.40%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $3.51
Upside: +184.90%
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $25.35
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $21.88
Upside: +178.79%
Feb 25, 2025
Reiterates: Buy
Price Target: $101
Current: $103.52
Upside: -2.43%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $14.38
Upside: -
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $8.76
Upside: +128.31%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.67
Upside: +3,808.60%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $0.74
Upside: +1,119.51%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.78
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $23.06
Upside: -17.59%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $131.64
Upside: -25.55%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $26.53
Upside: +28.16%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.66
Upside: +502.41%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $104.97
Upside: -53.32%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $805.43
Upside: -55.80%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $5.17
Upside: +16.05%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $13.69
Upside: +1,024.91%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $9.64
Upside: +55.68%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $30.84
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $16.33
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $4.75
Upside: +215.79%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $48.94
Upside: +24.64%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $1.49
Upside: +6,812.75%